Healthy subjects
Conditions
Brief summary
The geometric mean ratios of AUC and Cmax of rivaroxaban in absence and presence of sotorasib.
Detailed description
Description of the pharmacokinetics of sotorasib in healthy volunteers, by means of standard compartmental or non-compartmental pharmacokinetic methods., Description of the safety of sotorasib and rivaroxaban, graded with the most recent version (v6) of the Common Toxicity Criteria for Adverse Events.
Interventions
Sponsors
Stichting Radboud University Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The geometric mean ratios of AUC and Cmax of rivaroxaban in absence and presence of sotorasib. | — |
Secondary
| Measure | Time frame |
|---|---|
| Description of the pharmacokinetics of sotorasib in healthy volunteers, by means of standard compartmental or non-compartmental pharmacokinetic methods., Description of the safety of sotorasib and rivaroxaban, graded with the most recent version (v6) of the Common Toxicity Criteria for Adverse Events. | — |
Countries
Netherlands
Outcome results
None listed